Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Management

Noveris Announces Resignation Of CEO

By The Northwire Desk — AI Analysis Mar 10, 2026 · 16:05 NVRS · 0.33 Noveris Health Sciences Inc.
NVRS · Price

Executive Summary

  • Joshua Bartch resigned as director, president, and chief executive officer of Noveris Health Sciences Inc.
  • Jason Birmingham, previously chief strategy officer since February 2 2026, was appointed to assume the roles of director, president, and CEO.
  • The company issued a statement thanking Mr. Bartch for his service and wishing him well.

Key Details

  • Resignation effective as of the announcement date (March 10 2026).
  • Appointment of Jason Birmingham to all three positions previously held by Mr. Bartch.
  • Jason Birmingham’s prior role: Chief Strategy Officer, appointed on February 2 2026.
  • Contact information for the new CEO provided: email [email protected] and phone (888) 871‑3936.

Notable Quotes

(No direct quotes were included in the release.)

Read the original news release →

More from Noveris Health Sciences Inc.

Jun 05, 2026 · 16:20

Noveris Health Sciences Re-Engages R&D Partner on Psilocybin Pipeline Amid Stem Cell Pivot and Insider Sell-Off

M&A / Property May 21, 2026 · 14:12

Founder cashes out completely after boardroom shake‑up, casting a dark shadow over the sudden stem‑cell pivot.

Other Apr 29, 2026 · 12:05

Noveris Health Sciences Inc.

M&A / Property Apr 20, 2026 · 17:25

Noveris Health Sciences Inc.

Regulatory Mar 18, 2026 · 20:20

Noveris Announces Closing of Life Offering

Financings Mar 11, 2026 · 22:58

Noveris Announces Life Offering

Financings